Inbrija

Levodopa, the active ingredient in Inbrija, is a dopamine precursor presented as an 84 mg inhalation powder for inhalation use. It is used to treat OFF episodes in Parkinson's disease as an adjunctive therapy, providing rapid onset of symptom relief when oral medications are insufficient.

GNH USA supplies Inbrija as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with full EU market authorization and adherence to stringent quality standards. The company ensures cold‑chain logistics where required and offers comprehensive regulatory documentation to support importation.

Inbrija, a levodopa‑based inhalation therapy, is used in the management of Parkinson's disease motor fluctuations.

- Parkinson's disease: improves motor function during OFF episodes - OFF episodes: provides rapid symptom relief - Motor fluctuations: shortens duration of OFF periods

Inbrija may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Cough: mild irritation of the throat after inhalation - Throat irritation: transient soreness or dryness - Nausea: occasional upset stomach - Dizziness: light‑headed sensation, especially on standing

Serious or Rare Side Effects: - Dyskinesia: involuntary movements that may become pronounced - Orthostatic hypotension: sudden drop in blood pressure upon standing - Hallucinations or psychosis: rare neuropsychiatric events

Before initiating Inbrija, clinicians should consider several safety measures.

- Assess cardiovascular status: monitor blood pressure and heart rate - Evaluate respiratory function: avoid in patients with severe asthma or COPD - Review hepatic function: dose adjustment may be needed in liver impairment - Check for dyskinesia history: risk may increase with levodopa exposure - Instruct on proper inhalation technique: ensures optimal drug delivery - Store at room temperature: keep in original container, protect from moisture

Inbrija can interact with other medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may cause hypertensive crisis - Antipsychotics (dopamine antagonists): can reduce therapeutic effect - COMT inhibitors: increase levodopa plasma levels, raising risk of side effects

Moderate Interactions (Monitor Closely): - MAO‑B inhibitors: may enhance dopaminergic activity - Antihypertensive agents: risk of additive orthostatic hypotension - Iron or calcium supplements: may reduce levodopa absorption if taken simultaneously - SSRIs or other serotonergic drugs: monitor for serotonin syndrome signs